Tyrosine Hydroxylase and Dopamine Transporter Expression Following 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Induced Neurodegeneration of the Mouse Nigrostriatal Pathway

Journal of Neuroscience Research

Volumn 76, Issue 4, 2004, Pages 539-550

  Jakowec, Michael W ^a   Nixon, Kerry ^a   Hogg, Elizabeth ^a   McNeill, Tom ^a   Petzinger, Giselle M ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

DAT; MPTP; Neurotoxic injury; Parkinson's disease; Striatum; Substantia nigra

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DOPAMINE; DOPAMINE TRANSPORTER; ISOPROTEIN; MESSENGER RNA; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DEATH; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE METABOLISM; DOPAMINE UPTAKE; DOPAMINERGIC NERVE CELL; GENETIC TRANSCRIPTION; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MOUSE; NERVE CELL PLASTICITY; NERVE DEGENERATION; NEUROTOXICITY; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; REPRODUCIBILITY; WESTERN BLOTTING;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANALYSIS OF VARIANCE; ANIMALS; BLOTTING, WESTERN; CELL COUNT; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CORPUS STRIATUM; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MICE; MICE, INBRED C57BL; MPTP POISONING; NERVE TISSUE PROTEINS; NEURONS; SUBSTANTIA NIGRA; TIME FACTORS; TYROSINE 3-MONOOXYGENASE;

EID: 2342503324     PISSN: 03604012     EISSN: None     Source Type: Journal    
DOI: 10.1002/jnr.20114     Document Type: Article

References (54)

1. Acheson AL, Zigmond MJ. 1981. Short and long term changes in tyrosine hydroxylase activity in rat brain after subtotal destruction of central noradrenergic neurons. J Neurosci 1:493-504.
2. Alterio J, Ravassard P, Haavik J, Le Caer JP, Biguet NF, Waksman G, Mallet J. 1998. Human tyrosine hydroxylase isoforms. Inhibition by excess tetrahydropterin and unusual behavior of isoform 3 after camp-dependent protein kinase phosphorylation. J Biol Chem 273:10196-10201.
3. Ara J, Przedborski S, Naini AB, Jackson-Lewis V, Trifiletti RR, Horwitz J, Ischiropoulos H. 1998. Inactivation of tyrosine hydroxylase by nitration following exposure to peroxynitrite and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrideine (MPTP). Proc Natl Acad Sci USA 95:7659-7663.
4. Bernheimer H, Hornykiewicz O, Jellinger K, Seitelberger F. 1973. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci 20:415-455.
5. Betarbet R, Turner R, Chockkan V, DeLong MR., Allers KA, Walters J, Levey AI, Greenamyre JT. 1997. Dopaminergic neurons intrinsic to the primate striatum. J Neurosci 17:6761-6768.
6. Bezard E, Dovero S, Imbert C, Boraud T, Gross CE. 2000. Spontaneous long-term compensatory dopaminergic sprouting in MPTP-treated mice. Synapse 38:363-368.
7. Blanchard V, Chritin M, Vyas S, Savasta M, Feuerstein C, Agid Y, Javoy-Agid F, Raisman-Vozari R. 1995. Long-term induction of tyrosine hydroxylase expression: compensatory response to partial degeneration of the dopaminergic nigrostriatal system in the rat brain. J Neurochem 64:1669-1679.
8. Blanchard V, Anglade P, Dziewczapolski G, Savasta M, Agid Y, Raisman-Vozari R. 1996. Dopaminergic sprouting in the rat striatum after partial lesion of the substantia nigra. Brain Res 709:319-325.
9. Campbell DG, Hardie DG, Vulliet PR. 1986. Identification of four phosphorylation sites in the N-terminal region of tyrosine hydroxylase. J Biol Chem 261:10489-10492.
10. Chesselet MF, Weiss L, Wuenschell C, Tobin AJ, Affolter HU. 1987. Comparative distribution of mRNAs for glutamic acid decarboxylase, tyrosine hydroxylase, and tachykinins in the basal ganglia: an in situ hybridization study in the rodent brain. J Comp Neurol 262:125-140.
11. Eberling JL, Bankiewicz KS, Pivirotto P, Bringas J, Chen K, Nowotnik DP, Steiner JP, Budinger TF, Jagust WJ. 1999. Dopamine transporter loss and clinical changes in MPTP-lesioned primates. Brain Res 832:184-187.
12. Finkelstein DI, Stanic D, Parish CL, Tomas D, Dickson K, Home MK. 2000. Axonal sprouting following lesions of the rat substantia nigra. Neuroscience 97:99-112.
13. Fitzpatrick P. 1999. Tetrahydropterin-dependent amino acid hydroxylases. Annu Rev Biochem 68:355-381.
14. Grima B, Lamouroux A, Blanot F, Biguet NF, Mallet J. 1985. Complete coding sequence of rat tyrosine hydroxylase mRNA. Proc Natl Acad Sci USA 82:617-621.
15. Gundersen HJ. 1987. The efficiency of systematic sampling in stereology and its prediction. J Microsc 147:229-263.
16. Gutierrez LM, Ballesta JJ, Hidalgo MJ, Gandia L, Garcia AG, Reig JA. 1988. A two-dimensional electrophoresis study of phosphorylation and dephosphorylation of chromaffin cell proteins in response to a secretory stimulus. J Neurochem 51:1023-1030.
17. Harrington MG, Merril CR. 1984. Two-dimensional electrophoresis and "ultrasensitive" silver staining of cerebrospinal fluid proteins in neurological diseases. Clin Chem 30:1933-1937.
18. Haycock JW, Haycock DA. 1991. Tyrosine hydroxylase in rat brain dopaminergic nerve terminals. Multiple-site phosphorylation in vivo and in synaptosomes. J Biol Chem 266:5650-5657.
19. Haycock JW, Lew JY, Garcia-Espana A, Lee KY, Harada K, Meller E, Goldstein M. 1998. Role of serine-19 phosphorylation in regulating tyrosine hydroxylase studied with site- and phosphospecific antibodies and site-directed mutagenesis. J Neurochem 71:1670-1675.
20. Hefti F, Melamed E, Wurtman RJ. 1980. Partial lesions of the dopaminergic nigrostriatal system in rat brain: biochemical characterization. Brain Res 195:123-137.
21. Ho A, Blum M. 1998. Induction of interleukin-1 associated with compensatory dopaminergic sprouting in the denervated striatum of young mice: model of aging and neurodegenerative disease. J Neurosci 18:5614-5629.
22. Hoffman AF, Lupica CR, Gerhardt GA. 1998. Dopamine transporter activity in the substantia nigra and striatum assessed by high-speed chronoamperometric recordings in brain slices. J Pharmacol Exp Ther 287: 487-496.
23. Irwin I, Finnegan KT, DeLanney LE, Di Monte D, Langston JW. 1992. The relationship between aging, monoamine oxidase, striatal dopamine and the effects of MPTP in C57BL/6 mice: a critical reassessment. Brain Res 572:224-231.
24. Jackson-Lewis V, Jakowec M, Burke RE, Przedborski S. 1995. Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neurodegeneration 4:257-269.
25. Jakowec M. 1999. Glutamatergic compensatory mechanisms following MPTP lesioning in the basal ganglia of the mouse. Soc Neurosci Abstr. 25:1342.
26. Jakowec M, Fox AJ, Martin LJ, Kalb RG. 1995a. Quantitative and qualitative changes in AMPA receptor expression during spinal cord development. Neuroscience 67:893-907.
27. Jakowec MW, Yen L, Kalb RG. 1995b. In situ hybridization analysis of AMPA receptor subunit gene expression in the developing rat spinal cord. Neuroscience 67:909-920.
28. Jakowec MW, Jackson-Lewis V, Chen X, Langston JW, Przedborski S. 1998. The postnatal development of AMPA receptors in the basal ganglia of the rat. Dev Neurobiol 20:19-33.
29. Jakowec MW, Donaldson DM, Barba J, Petzinger GM. 2001. The post-natal expression of α-synuclein in the substantia nigra and striatum of the rodent. Dev Neurosci 23:91-99.
30. Jarrott B, Geffen LB. 1972. Rapid axoplasmic transport of tyrosine hydroxylase in relation to other cytoplasmic constituents. Proc Natl Acad Sci USA 69:3440-3442.
31. Javoy-Agid F, Hirsch EC, Dumas S, Duyckaerts C, Mallet J, Agid Y. 1990. Decreased tyrosine hydroxylase messenger RNA in the surviving dopamine neurons of the substantia nigra in Parkinson's disease: an in situ hybridization study. Neuroscience 38:245-253.
32. Kasmer A, Hirsch EC, Herrero MT, Javoy-Agid F, Agid Y. 1993. Immunocytochemical quantification of tyrosine hydroxylase at a cellular level in the mesencephalon of control subjects and patients with Parkinson's and Alzheimer's disease. J Neurochem 61:1024-1034.
33. Kay JN, Blum M. 2000. Differential response of ventral midbrain and striatal progenitor cells to lesions of the nigrostriatal dopaminergic projection. Dev Neurosci 22:56-67.
34. Kilbourn MR, Kuszpit K, Sherman P. 2000. Rapid and differential losses of in vivo dopamine transporter (DAT) and vesicular monoamine transporter (VMAT2) radioligand binding in MPTP-treated mice. Synapse 35:250-255.
35. Kilpatrick IC, Jones MW, Phillipson OT. 1986. A semiautomated analysis method for catecholamines, indoleamines, and some prominent metabolites in microdissected regions of the nervous system: an isocratic HPLC technique employing coulometric detection and minimal sample preparation. J Neurochem 46:1865-1876.
36. Laemmli UK. 1970. Cleavage of structural proteins during the assembly of the head of the bacteriophage T4. Nature 227:680-685.
37. Le Bourdelles B, Horellou P, Le Caer JP, Denefle P, Latta M, Haavik J, Guibert B, Mayaux JF, Mallet J. 1991. Phosphorylation of human recombinant tyrosine hydroxylase isoforms 1 and 2: an additional phosphorylated residue in isoform 2, generated through alternative splicing. J Biol Chem 266:17124-17130.
38. Lloyd KG, Davidson L, Hornykiewicz O. 1975. The neurochemistry of Parkinson's disease: effect of L-dopa therapy. J Pharmacol Exp Ther 195:453-464.
39. Mogi M, Harada M, Kiuchi K, Kojima K, Kondo T, Narabayashi H, Rausch D, Riederer P, Jellinger K, Nagatsu T. 1988. Homospecific activity (activity per enzyme protein) of tyrosine hydroxylase increases in parkinsonian brain. J Neural Transm 72:77-82.
40. Onn S, Berger TW, Stricker EM, Zigmond MJ. 1986. Effects of intraventricular 6-hydroxydopamine on the dopaminergic innervation of striatum: histochemical and neurochemical analysis. Brain Res 376:8-19.
41. Pakkenberg B, Moller A, Gundersen HJ, Mouritzen Dam A, Pakkenberg H. 1991. The absolute number of nerve cells in substantia nigra in normal subjects and in patients with Parkinson's disease estimated with an unbiased stereological method. J Neurol Neurosurg Psychiatry 54:30-33.
42. Pasinetti GM, Lerner SP, Johnson SA, Morgan DG, Telford NA, Finch CE. 1989. Chronic lesions differentially decrease tyrosine hydroxylase messenger RNA in dopaminergic neurons of the substantia nigra. Brain Res Mol Brain Res 5:203-209.
43. Pasinetti GM, Osterburg HH, Kelly AB, Kohama S, Morgan DG, Reinhard JF, Stellwagen RH, Finch CE. 1992. Slow changes of tyrosine hydroxylase gene expression in dopaminergic brain neurons after neurotoxin lesioning: a model for neuron aging. Brain Res Mol Brain Res 13:63-73.
44. Ricaurte GA, Langston JW, DeLanney LE, Irwin I, Peroutka SJ, Forno LS. 1986. Fate of nigrostriatal neurons in young mature mice given 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: a neurochemical and morphological reassessment. Brain Res 376:117-124.
45. Ricaurte GA, DeLanney LE, Irwin I, Langston JW. 1987a. Older dopaminergic neurons do not recover from the effects of MPTP. Neuropharmacology 26:97-99.
46. Ricaurte GA, Irwin I, Forno LS, DeLanney LE, Langston E, Langston JW. 1987b. Aging and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced degeneration of dopaminergic neurons in the substantia nigra. Brain Res 403:43-51.
47. Rothblat DS, Schneider JS. 1999. Regional differences in striatal dopamine uptake and release associated with recovery from MPTP-induced parkinsonism: an in vivo electrochemical study. J Neurochem 72:724-733.
48. Sirinathsinghji DJ, Kupsch A, Mayer E, Zivin M, Pufal D, Oertel WH. 1992. Cellular localization of tyrosine hydroxylase mRNA and cholecystokinin mRNA-containing cells in the ventral mesencephalon of the common marmoset: effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Brain Res Mol Brain Res 12:267-274.
49. Song DD, Haber SN. 2000. Striatal responses to partial dopaminergic lesion: evidence for compensatory sprouting. J Neurosci 20:5102-5114.
50. Sutherland C, Alterio J, Campbell DG, Le Bourdelles B, Mallet J, Haavik J, Cohen P. 1993. Phosphorylation and activation of human tyrosine hydroxylase in vitro by mitogen-activated protein (MAP) kinase and MAP-kinase-activated kinases 1 and 2. Eur J Biochem 217:715-722.
51. Thomas JR, Salazar W, Landers DM. 1991. What is missing in P < .05? Effect size. Res Q Exerc Sport 62:344-348.
52. Towbin H, Staehelin T, Gordon J. 1979. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets. Procedures and some applications. Proc Natl Acad Sci USA 76:4350-4354.
53. Zigmond MJ, Acheson AL, Stachowiak MK, Strickerman EM. 1984. Neurochemical compensation after nigrostriatal bundle injury in an animal models of preclinical parkinsonism. Arch Neurol 41:856-861.
54. Zigmond RE, Schwarzschild MA, Rittenhouse AR. 1989. Acute regulation of tyrosine hydroxylase by nerve activity and by neurotransmitters via phosphorylation. Annu Rev Neurosci 12:415-461.